Last update: Nov. 29, 2019

Armodafinil

Decreased level of risk

New scientific evidences have driven the Apilam staff to update the level of risk associated to this product.
Former level of risk, which was High Risk, is now set to Low Risk.

Level of risk reviewed on Nov. 27, 2019

Low Risk for breastfeeding


Moderately safe. Probably compatible.
Mild risk possible. Follow up recommended.
Read the Comment.

Estimulante central inhibidor selectivo de la recaptación de dopamina y noradrenalina. Es el enantiomero R del modafinilo, con similares propiedades farmacológicas y efectos que el modafinilo, ya que es su metabolito activo.
Utilizado en la narcolepsia.
Administración oral en una dosis diaria.

El modafinilo se excreta en leche materna en cantidad clínicamente no significativa (Aurora 2018) y no se han observado problemas en seis lactantes cuyas madres tomaban modafinilo (Calvo 2018).

El modafinilo puede reducir los niveles de prolactina (Samuels 2006).

Una madre nos ha comunicado nerviosismo y dificultad para dormir en sus hijas lactantes que le obligó a suspender el tratamiento (edad de niñas y dosis no especificadas).

Hasta conocer más datos publicados sobre este fármaco en relación con la lactancia, pueden ser preferibles alternativas conocidas más seguras, especialmente durante el periodo neonatal y en caso de prematuridad.


See below the information of these related products:

Alternatives

Suggestions made at e-lactancia are done by APILAM´s pediatricians and pharmacists, and are based on updated scientific publications.
It is not intended to replace the relationship you have with your doctor but to compound it.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Armodafinil is also known as


Armodafinil in other languages or writings:

Group

Armodafinil belongs to this group or family:

Tradenames

Main tradenames from several countries containing Armodafinil in its composition:

Pharmacokinetics

Variable Value Unit
Molecular weight 273 daltons
Protein Binding 60 %
VD 0,6 l/Kg
pKa 8,84 -
Tmax 2 - 4 hours
T1/2 15 hours
Theoretical Dose 0,18 mg/Kg/d
Relative Dose 5,3 %

References

  1. Calvo-Ferrandiz E, Peraita-Adrados R. Narcolepsy with cataplexy and pregnancy: a case-control study. J Sleep Res. 2018 Apr;27(2):268-272. Abstract Full text (link to original source)
  2. Aurora S, Aurora N, Datta P, Rewers-Felkins K, Baker T, Hale TW. Evaluating Transfer of Modafinil Into Human Milk During Lactation: A Case Report. J Clin Sleep Med. 2018 Dec 15;14(12):2087-2089. Abstract Full text (link to original source) Full text (in our servers)
  3. FDA. Armodafinil (Nuvigil). Drug Summary. 2017 Full text (link to original source) Full text (in our servers)
  4. Armodafinilo Ficha técnica 2010 Full text (in our servers)
  5. Wise MS, Arand DL, Auger RR, Brooks SN, Watson NF; American Academy of Sleep Medicine. Treatment of narcolepsy and other hypersomnias of central origin. Sleep. 2007 Abstract Full text (link to original source) Full text (in our servers)
  6. Samuels ER, Hou RH, Langley RW, Szabadi E, Bradshaw CM. Comparison of pramipexole and modafinil on arousal, autonomic, and endocrine functions in healthy volunteers. J Psychopharmacol. 2006 Nov;20(6):756-70. Epub 2006 Jan 9. Abstract

Total visits

2,779

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write to us at elactancia.org@gmail.com

e-lactancia is a resource recommended by Confederación Nacional de Pediatría (CONAPEME) from Mexico

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM